Multisystem Inflammatory Syndrome therapies in children (MISTIC) : A randomized trial
© 2023 The Authors..
Background: Multisystem Inflammatory Syndrome in Children (MIS-C), which occurs 2-6 weeks after initial exposure to SARS-CoV-2, was first identified in early 2020 when patients presented with fever and significant inflammation, often requiring management in the intensive care unit. To date, there has been no clinical trial to determine the most effective treatment. This study compares anti-inflammatory treatments that were selected based on current treatments for Kawasaki disease, a coronary artery vasculitis that shares many clinical features with MIS-C.
Methods: This randomized, comparative effectiveness trial of children with MIS-C uses the small N Sequential Multiple Assignment Randomized Trial (snSMART) design for rare diseases to compare multiple therapies within an individual. Study participants were treated first with intravenous immunoglobulin (IVIG), and if needed, subjects were then randomized to one of three additional treatments (steroids, anakinra, or infliximab). Participants were re-randomized to remaining treatments if they did not demonstrate clinical improvement.
Conclusion: This trial continues to enroll eligible participants to determine the most effective therapies in addition to IVIG and best order in which to use them to treat MIS-C.
Trial Registration: NCT04898231.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Contemporary clinical trials communications - 32(2023) vom: 01. Apr., Seite 101060 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jain, Sonia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 01.02.2023 published: Print-Electronic ClinicalTrials.gov: NCT04898231 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.conctc.2023.101060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352051795 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352051795 | ||
| 003 | DE-627 | ||
| 005 | 20231226052835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.conctc.2023.101060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352051795 | ||
| 035 | |a (NLM)36694613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jain, Sonia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multisystem Inflammatory Syndrome therapies in children (MISTIC) |b A randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04898231 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background: Multisystem Inflammatory Syndrome in Children (MIS-C), which occurs 2-6 weeks after initial exposure to SARS-CoV-2, was first identified in early 2020 when patients presented with fever and significant inflammation, often requiring management in the intensive care unit. To date, there has been no clinical trial to determine the most effective treatment. This study compares anti-inflammatory treatments that were selected based on current treatments for Kawasaki disease, a coronary artery vasculitis that shares many clinical features with MIS-C | ||
| 520 | |a Methods: This randomized, comparative effectiveness trial of children with MIS-C uses the small N Sequential Multiple Assignment Randomized Trial (snSMART) design for rare diseases to compare multiple therapies within an individual. Study participants were treated first with intravenous immunoglobulin (IVIG), and if needed, subjects were then randomized to one of three additional treatments (steroids, anakinra, or infliximab). Participants were re-randomized to remaining treatments if they did not demonstrate clinical improvement | ||
| 520 | |a Conclusion: This trial continues to enroll eligible participants to determine the most effective therapies in addition to IVIG and best order in which to use them to treat MIS-C | ||
| 520 | |a Trial Registration: NCT04898231 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anakinra | |
| 650 | 4 | |a IVIG, Intravenous immunoglobulin | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Multisystem inflammatory syndrome in children (MIS-C) | |
| 650 | 4 | |a Randomized clinical trial | |
| 650 | 4 | |a Steroids | |
| 650 | 4 | |a snSMART | |
| 650 | 4 | |a snSMART, small N Sequential Multiple Assignment Randomized Trial | |
| 700 | 1 | |a He, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Kiana |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Jane C |e verfasserin |4 aut | |
| 700 | 1 | |a Tremoulet, Adriana H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials communications |d 2015 |g 32(2023) vom: 01. Apr., Seite 101060 |w (DE-627)NLM257485147 |x 2451-8654 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g day:01 |g month:04 |g pages:101060 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.conctc.2023.101060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |b 01 |c 04 |h 101060 | ||